Lipocine (LPCN) EPS (Basic) (QoQ) (2013 - 2025)
Lipocine (LPCN) EPS (Basic) (QoQ) (2013 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.24 Bn | 131.39 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.01 Bn | 78.02 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.61 Bn | 60.42 Bn | 1.37 Bn |
| 4 | Moderna | 56.92 Bn | 51.78 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.27 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.77 Bn | 9.38 Bn | 668.28 Mn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - |
| 10 | Lipocine | 11.42 Mn | -12.49 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -42.85% |
| Jun 30, 2025 | -18.20% |
| Mar 31, 2025 | -204.45% |
| Dec 31, 2024 | 180.46% |
| Sep 30, 2024 | 27.75% |
| Jun 30, 2024 | -186.88% |
| Mar 31, 2024 | 252.62% |
| Dec 31, 2023 | 65.54% |
| Sep 30, 2023 | -85.40% |
| Jun 30, 2023 | 8.81% |
| Mar 31, 2023 | -73.46% |
| Dec 31, 2022 | 7.39% |
| Sep 30, 2022 | 8.47% |
| Jun 30, 2022 | 24.70% |
| Mar 31, 2022 | -127.20% |
| Dec 31, 2021 | 516.09% |
| Sep 30, 2021 | 54.75% |
| Jun 30, 2021 | -87.49% |
| Mar 31, 2021 | 49.22% |
| Dec 31, 2020 | -21.77% |